gpASIT+TM
Sponsors
BioTech Tools S.A., ASIT Biotech S.A.
Conditions
Grass Pollen AllergyHay FeverSeasonal Allergic Rhinoconjunctivitis
Phase 1
Safety and Tolerance Study of Grass Pollen-derived Peptides to Treat Allergic Rhinitis
CompletedNCT00813046
Start: 2008-12-31End: 2009-01-31Updated: 2014-05-26
Safety Study of Grass Pollen-derived Peptides to Treat Seasonal Allergic Rhinoconjunctivitis
CompletedNCT00833066
Start: 2009-02-28End: 2009-11-30Updated: 2011-11-17
Clinical Safety and Tolerability Study of gpASIT+TM and gpASIT+TM/Immunoregulating Adjuvant to Treat Seasonal Grass Pollen Rhinoconjunctivitis
CompletedNCT01111279
Start: 2010-03-31End: 2010-11-30Target: 27Updated: 2011-03-01
Phase 2
Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis
CompletedNCT01308021
Start: 2010-12-31End: 2011-12-31Updated: 2014-05-26
Safety of gpASIT+TM Subcutaneously Administered to Hay Fever Patients With or Without Immunoregulating Adjuvant
CompletedNCT01506375
Start: 2011-11-30End: 2013-04-30Updated: 2014-05-26
Safety, Clinical Tolerability and Immunogenicity of Increasing Doses of gpASIT+TM
CompletedNCT02156791
Start: 2013-08-31End: 2013-12-31Updated: 2014-06-06
Phase 3
Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis
CompletedNCT02560948
Start: 2015-12-31End: 2016-08-31Updated: 2018-10-11
Clinical Efficacy and Safety of Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis
NCT03724240
Start: 2019-01-02End: 2019-12-31Target: 624Updated: 2018-10-30